{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:47:05Z","timestamp":1791953225879,"version":"4.3.4"},"reference-count":174,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>The increasing use of next-generation sequencing (NGS), including multigene panels and exome and genome sequencing, has led to increased identification of rare and previously unreported variants in Mendelian disorders, though evidence supporting their clinical interpretation remains limited. In Fabry disease (FD), this issue is particularly relevant because the interpretation of individual GLA gene variants contributes to establishing whether a variant supports the diagnosis, with an impact on treatment decisions. In fact, FD is characterized by a phenotypic heterogeneity depending on patients\u2019 biological sex and the underlying GLA variant. This represents the main reason why integrating genetic data with phenotypic expression is challenging, and defining the pathogenic role of novel variants remains complex. Early discrimination between pathogenic and non-pathogenic GLA variants is essential. However, variant classification, a definitive diagnosis of FD, and the decision to start disease-specific treatment are separate steps. A variant of uncertain significance (VUS), an isolated biochemical abnormality or non-specific organ involvement, is not in itself sufficient to establish the diagnosis or justify enzyme replacement or chaperone therapy. In fact, the most severe cases of FD have a significantly compromised quality of life up to reduced life expectancy, especially with regard to cardiac and renal complications. In recent years, some GLA variants have been reclassified following investigation and clinical observations by multidisciplinary working groups, making it possible to better define if they are pathogenic or not. Regardless of the clinical scenario leading to the identification of a novel GLA variant (i.e., family screening, neonatal screening, clinical profile suggestive of FD, incidental finding), any genetic finding becomes relevant when it is complemented by laboratory, clinical and instrumental investigations that require a concerted effort among the many health care professionals involved in the diagnostic process. The present work summarizes the outcomes of a series of expert meetings with the aim to provide some shared and practical indications for managing the genetic report of a novel GLA variant in order to promptly start the most suitable diagnostic journey and assess corresponding phenotype and clinical characterization.<\/jats:p>","DOI":"10.3390\/jcm15197655","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:35:56Z","timestamp":1790944556000},"page":"7655","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel GLA Variants: 10 Experts\u2019 Tips for the Clinical Assessment of Fabry Disease"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1302-6846","authenticated-orcid":false,"given":"Federico","family":"Pieruzzi","sequence":"first","affiliation":[{"name":"Nephrology, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy"},{"name":"School of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8507-8939","authenticated-orcid":false,"given":"Renzo","family":"Mignani","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna, 40126 Bologna, Italy"},{"name":"Nephrology Department, IRCCS S. Orsola Hospital, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8420-8447","authenticated-orcid":false,"given":"Sandro","family":"Feriozzi","sequence":"additional","affiliation":[{"name":"Nephrology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7530-818X","authenticated-orcid":false,"given":"Marialuisa","family":"Zedde","sequence":"additional","affiliation":[{"name":"Neurology Unit, Stroke Unit, Azienda Unit\u00e0 Sanitaria Locale-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Carraro","sequence":"additional","affiliation":[{"name":"Nephrology, Dialysis and Transplant Unit, Department of Medicine, Padova University Hospital, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5954-3796","authenticated-orcid":false,"given":"Cristina","family":"Chimenti","sequence":"additional","affiliation":[{"name":"Department of Medical and Cardiovascular Sciences, La Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[{"name":"Department of Public Health, Federico II University of Naples, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-350X","authenticated-orcid":false,"given":"Marco","family":"Spada","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Turin, 10124 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Morrone","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Genetics of Neurometabolic Diseases, Department of Neuroscience and Human Genetics, Meyer Children\u2019s Hospital IRCCS, 50139 Florence, Italy"},{"name":"Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, 50139 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry\u2019s disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/jmg-2022-108523","article-title":"Prevalence of Fabry disease-causing variants in the UK Biobank","volume":"60","author":"Gilchrist","year":"2023","journal-title":"J. Med. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"110114","DOI":"10.1016\/j.ymgme.2026.110114","article-title":"Over ten years of newborn screening for LSDs in Tuscany (Italy): Epidemiology, novel variants, and the pseudodeficiency burden","volume":"148","author":"Malvagia","year":"2026","journal-title":"Mol. Genet. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/jmedgenet-2019-106467","article-title":"Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: A consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroup. Fabry registry genotype\u2013phenotype classification","volume":"57","author":"Germain","year":"2020","journal-title":"J. Med. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: A multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Anania, M., Pieruzzi, F., Giacalone, I., Trezzi, B., Marsana, E.M., Roggero, L., Francofonte, D., Stefanoni, M., Vinci, M., and Zizzo, C. (2025). Identification of Four New Mutations in the GLA Gene Associated with Anderson-Fabry Disease. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26020473"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e2029","DOI":"10.1002\/mgg3.2029","article-title":"X-chromosomal inactivation patterns in women with Fabry disease","volume":"10","author":"Rickert","year":"2022","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Thompson, S.E., Roy, A., Geberhiwot, T., Gehmlich, K., and Steeds, R.P. (2025). Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies. Biomedicines, 13.","DOI":"10.3390\/biomedicines13030624"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s12325-024-03041-2","article-title":"Effects of Current Therapies on Disease Progression in Fabry Disease: A Narrative Review for Better Patient Management in Clinical Practice","volume":"42","author":"Mignani","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2022.07.010","article-title":"An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease","volume":"137","author":"Germain","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2147\/TCRM.S475744","article-title":"Experts\u2019 Opinion in Fabry Disease Management and the Unmet Medical Need: The Saudi Perspective","volume":"20","author":"Alfadhel","year":"2024","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_13","first-page":"424","article-title":"Genetic and phenotypic profile of Fabry disease in the population of Vale do Paraiba and Eastern S\u00e3o Paulo","volume":"45","author":"Paz","year":"2023","journal-title":"J. Bras. Nefrol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e004252","DOI":"10.1161\/CIRCGEN.123.004252","article-title":"Impact of GLA Variant Classification on the Estimated Prevalence of Fabry Disease: A Systematic Review and Meta-Analysis of Screening Studies","volume":"16","author":"Monda","year":"2023","journal-title":"Circ. Genom. Precis Med."},{"key":"ref_16","first-page":"e64127","article-title":"Cases of Fabry Disease in Which Pathogenic Variants Are Not Detected in Parent-Child Pairs","volume":"16","author":"Akeho","year":"2024","journal-title":"Cureus"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/jimd.12240","article-title":"Is the alpha-galactosidase A variant p.Asp313Tyr (p.D313Y) pathogenic for Fabry disease? A systematic review","volume":"43","author":"Effraimidis","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/jhg.2010.58","article-title":"Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns","volume":"55","author":"Lee","year":"2010","journal-title":"J. Hum. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41431-017-0043-9","article-title":"Points to consider for laboratories reporting results from diagnostic genomic sequencing","volume":"26","author":"Vears","year":"2018","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/gim.2016.152","article-title":"A survey of current practices for genomic sequencing test interpretation and reporting processes in US laboratories","volume":"19","author":"McLaughlin","year":"2017","journal-title":"Genet. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.21037\/atm-19-4510","article-title":"GLA missense and promoter variants co-segregating in a Chinese family with Fabry disease","volume":"8","author":"Dong","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Singh, J., Santosh, P., and Ramaswami, U. (2025). Epigenetic Mechanisms in Fabry Disease: A Thematic Analysis Linking Differential Methylation Profiles and Genetic Modifiers to Disease Phenotype. Curr. Issues Mol. Biol., 47.","DOI":"10.3390\/cimb47100855"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"107714","DOI":"10.1016\/j.ymgme.2023.107714","article-title":"Prevalence of Fabry disease in patients with chronic kidney disease: A systematic review and meta-analysis","volume":"140","author":"Linares","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Sawada, T., Kido, J., Sugawara, K., and Nakamura, K. (2021). High-Risk Screening for Fabry Disease: A Nationwide Study in Japan and Literature Review. Diagnostics, 11.","DOI":"10.3390\/diagnostics11101779"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gragnaniello, V., Burlina, A.P., Commone, A., Gueraldi, D., Puma, A., Porc\u00f9, E., Stornaiuolo, M., Cazzorla, C., and Burlina, A.B. (2023). Newborn Screening for Fabry Disease: Current Status of Knowledge. Int. J. Neonatal Screen, 9.","DOI":"10.3390\/ijns9020031"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13023-020-01494-6","article-title":"Fabry disease screening in high-risk populations in Japan: A nationwide study","volume":"15","author":"Yoshida","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1159\/000541207","article-title":"Fabry disease with genetic variants of unknown significance and concomitant IgA nephropathy","volume":"49","author":"Zhou","year":"2024","journal-title":"Kidney Blood Press Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000479895","article-title":"A Novel Missense GLA Mutation (p.G35V) Detected in Hemodialysis Screening Leads to Severe Systemic Manifestations of Fabry Disease in Men and Women","volume":"138","author":"Veloso","year":"2018","journal-title":"Nephron"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13023-022-02319-4","article-title":"The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: A Russian nationwide screening program using NGS technology","volume":"17","author":"Savostyanov","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s40246-024-00697-3","article-title":"Long-read sequencing enables comprehensive molecular genetic diagnosis of Fabry disease","volume":"18","author":"Yao","year":"2024","journal-title":"Hum. Genom."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13073-023-01192-5","article-title":"The clinical utility of rapid exome sequencing in a consanguineous population","volume":"15","author":"Monies","year":"2023","journal-title":"Genome Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"D862","DOI":"10.1093\/nar\/gkv1222","article-title":"ClinVar: Public archive of interpretations of clinically relevant variants","volume":"44","author":"Landrum","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/gim.2012.19","article-title":"Communicating new knowledge on previously reported genetic variants","volume":"14","author":"Aronson","year":"2012","journal-title":"Genet. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1089\/gtmb.2011.0328","article-title":"A report template for molecular genetic tests designed to improve communication between the clinician and laboratory","volume":"16","author":"Scheuner","year":"2012","journal-title":"Genet. Test. Mol. Biomark."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e00794","DOI":"10.1002\/mgg3.794","article-title":"Fabry pedigree analysis: A successful program for targeted genetic approach","volume":"7","author":"Rozenfeld","year":"2019","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e63552","DOI":"10.1002\/ajmg.a.63552","article-title":"Experience with cascade screening: A comprehensive family pedigree analysis of two index patients with Fabry disease","volume":"194","author":"Kisa","year":"2024","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e1666","DOI":"10.1002\/mgg3.1666","article-title":"The benefits and challenges of family genetic testing in rare genetic diseases-lessons from Fabry disease","volume":"9","author":"Germain","year":"2021","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/cge.14102","article-title":"Challenging the traditional approach for interpreting genetic variants: Lessons from Fabry disease","volume":"101","author":"Germain","year":"2022","journal-title":"Clin. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40246-022-00407-x","article-title":"Expanding ACMG variant classification guidelines into a general framework","volume":"16","author":"Masson","year":"2022","journal-title":"Hum. Genom."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ymgme.2014.11.004","article-title":"The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: Data from individual patients and family studies","volume":"114","author":"Ferreira","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e1912","DOI":"10.1002\/mgg3.1912","article-title":"Gene variants of unknown significance in Fabry disease: Clinical characteristics of c.376A>G (p.Ser126Gly)","volume":"10","author":"Lau","year":"2022","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/gim.2017.26","article-title":"Using high-resolution variant frequencies to empower clinical genome interpretation","volume":"19","author":"Whiffin","year":"2017","journal-title":"Genet. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/mgg3.389","article-title":"Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study","volume":"6","author":"Germain","year":"2018","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"107715","DOI":"10.1016\/j.ymgme.2023.107715","article-title":"Variant classification for Pompe disease; ACMG\/AMP specifications from the ClinGen Lysosomal Diseases Variant Curation Expert Panel","volume":"140","author":"Goldstein","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Lukas, J., Giese, A.K., Markoff, A., Grittner, U., Kolodny, E., Mascher, H., Lackner, K.J., Meyer, W., Wree, P., and Saviouk, V. (2013). Functional characterisation of alpha-galactosidase A mutations as a basis for a new classification system in Fabry disease. PLoS Genet., 9.","DOI":"10.1371\/journal.pgen.1003632"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1086\/339431","article-title":"Alternative splicing in the alpha-galactosidase A gene: Increased exon inclusion results in the Fabry cardiac phenotype","volume":"70","author":"Ishii","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e981","DOI":"10.1002\/mgg3.981","article-title":"Renal globotriaosylceramide deposits for Fabry disease linked to uncertain pathogenicity gene variant c.352C>T\/p.Arg118Cys: A family study","volume":"7","year":"2019","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e70103","DOI":"10.1002\/jimd.70103","article-title":"Clinical and biochemical characterization of Fabry disease associated GLA gene variants: Data from a large cohort of 469 thousand genotyped subjects of the UK Biobank database","volume":"48","author":"Giammanco","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: Influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF03401671","article-title":"Fabry disease: Thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes","volume":"3","author":"Eng","year":"1997","journal-title":"Mol. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13023-016-0441-z","article-title":"Alpha-galactosidase A p.A143T, a non-Fabry disease-causing variant","volume":"11","author":"Lenders","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_52","first-page":"1186","article-title":"Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease","volume":"53","author":"Eng","year":"1993","journal-title":"Am. J. Hum. Genet."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e200271","DOI":"10.1212\/NXG.0000000000200271","article-title":"A retrospective cohort study of the GLA c.937G>T, p.Asp313Tyr variant with no evidence of an association with Fabry disease","volume":"11","author":"Boettcher","year":"2025","journal-title":"Neurol. Genet."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","article-title":"High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population","volume":"2","author":"Lin","year":"2009","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ymgme.2017.03.005","article-title":"Genetic epidemiological study doesn\u2019t support GLA IVS4+919G>A variant is a significant mutation in Fabry disease","volume":"121","author":"Chiang","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ajmg.c.31395","article-title":"Refining the structure and content of clinical genomic reports","volume":"166","author":"Dorschner","year":"2014","journal-title":"Am. J. Med. Genet. Part C Semin Med. Genet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ajhg.2013.08.006","article-title":"Actionable, pathogenic incidental findings in 1000 participants\u2019 exomes","volume":"93","author":"Dorschner","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2147\/TCRM.S247814","article-title":"Diagnosis and Screening of Patients with Fabry Disease","volume":"16","author":"Vardarli","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.amjms.2020.07.011","article-title":"When and How to Diagnose Fabry Disease in Clinical Pratice","volume":"360","author":"Michaud","year":"2020","journal-title":"Am. J. Med. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ymgme.2020.04.006","article-title":"A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females","volume":"130","author":"Stiles","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/cge.13936","article-title":"Accuracy diagnosis improvement of Fabry disease from dried blood spots: Enzyme activity, lyso-Gb3 accumulation and GLA gene sequencing","volume":"99","author":"Santotoribio","year":"2021","journal-title":"Clin. Genet."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Duro, G., Zizzo, C., Cammarata, G., Burlina, A., Burlina, A., Polo, G., Scalia, S., Oliveri, R., Sciarrino, S., and Francofonte, D. (2018). Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19123726"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: Formation of glycosphingoid bases during deficiency of glycosidases","volume":"590","author":"Ferraz","year":"2016","journal-title":"FEBS Lett."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/gim.2018.31","article-title":"Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis","volume":"21","author":"Maruyama","year":"2019","journal-title":"Genet. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","article-title":"Plasma lyso-Gb3: A biomarker for monitoring fabry patients during enzyme replacement therapy","volume":"22","author":"Sakuraba","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41436-020-00968-z","article-title":"Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease","volume":"23","author":"Bichet","year":"2021","journal-title":"Genet. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e009098","DOI":"10.1161\/JAHA.118.009098","article-title":"Elevated inflammatory plasma biomarkers in patients with Fabry disease: A critical link to heart failure with preserved ejection fraction","volume":"7","author":"Yogasundaram","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ymgme.2018.11.005","article-title":"Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: Results from the SOPHIA study","volume":"126","author":"Weidemann","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes: Lyso-Gb3 defines Fabry disease","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_72","first-page":"100993","article-title":"A new multiplex analysis of glucosylsphingosine and globotriaosylsphingosine in dried blood spots by tandem mass spectrometry","volume":"37","author":"Roosens","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e000277","DOI":"10.1136\/bmjresp-2018-000277","article-title":"Pulmonary involvement in Fabry disease: Effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy","volume":"5","author":"Franzen","year":"2018","journal-title":"BMJ Open Respir. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.2215\/CJN.0000000000000239","article-title":"Early Risk Stratification for Natural Disease Course in Fabry Patients Using Plasma Globotriaosylsphingosine Levels","volume":"18","author":"Sayed","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/jmedgenet-2020-107338","article-title":"Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease","volume":"59","author":"Nowak","year":"2022","journal-title":"J. Med. Genet."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/cge.12386","article-title":"The kidney in Fabry\u2019s disease","volume":"86","author":"Pisani","year":"2014","journal-title":"Clin. Genet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/ndt\/gfy357","article-title":"Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: A longitudinal cohort study","volume":"34","author":"Madsen","year":"2019","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000493469","article-title":"Glomerular Hyperfiltration: An Early Marker of Nephropathy in Fabry Disease","volume":"141","author":"Riccio","year":"2019","journal-title":"Nephron"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ndt\/gfp554","article-title":"End-stage renal disease in patients with Fabry disease: Natural history data from the Fabry Registry","volume":"25","author":"Ortiz","year":"2010","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2054358120985627","DOI":"10.1177\/2054358120985627","article-title":"Renal Manifestations of Fabry Disease: A Narrative Review","volume":"8","author":"Silva","year":"2021","journal-title":"Can. J. Kidney Health Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1750-1172-8-116","article-title":"Fibrosis: A key feature of Fabry disease with potential therapeutic implications","volume":"8","author":"Weidemann","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Wijburg, F.A., B\u00e9nichou, B., Bichet, D.G., Clarke, L.A., Dostalova, G., Fainboim, A., Fellgiebel, A., Forcelini, C., An Haack, K., and Hopkin, R.J. (2015). Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124987"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/jmedgenet-2015-103471","article-title":"Antiproteinuric therapy and Fabry nephropathy: Factors associated with preserved kidney function during agalsidase-beta therapy","volume":"52","author":"Warnock","year":"2015","journal-title":"J. Med. Genet."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Simonetta, I., Tuttolomondo, A., Daidone, M., and Pinto, A. (2020). Biomarkers in Anderson\u2013Fabry Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218080"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Jaurretche, S., Conde, H., Gonzalez Schain, A., Ruiz, F., Sgro, M.V., and Venera, G. (2022). Biomarkers for Monitoring Renal Damage Due to Fabry Disease in Patients Treated with Migalastat: A Review for Nephrologists. Genes, 13.","DOI":"10.3390\/genes13101751"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Levstek, T., Vujkovac, B., and Trebusak Podkrajsek, K. (2020). Biomarkers of Fabry Nephropathy: Review and Future Perspective. Genes, 11.","DOI":"10.3390\/genes11091091"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Romejko, K., Markowska, M., and Niemczyk, S. (2023). The Review of Current Knowledge on Neutrophil Gelatinase-Associated Lipocalin (NGAL). Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310470"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000500570","article-title":"Evaluation of Beta 2-Microglobulin, Cystatin C, and Lipocalin-2 as Renal Biomarkers for Patients with Fabry Disease","volume":"143","author":"Braga","year":"2019","journal-title":"Nephron"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12967-016-1049-8","article-title":"Increased urinary CD80 excretion and podocyturia in Fabry disease","volume":"14","author":"Trimarchi","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"13","DOI":"10.20517\/rdodj.2023.56","article-title":"Biomarkers in anderson-Fabry disease: What should we use in the clinical practice?","volume":"3","author":"Aguiar","year":"2024","journal-title":"Rare Dis. Orphan Drugs J."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Waldek, S., and Feriozzi, S. (2014). Fabry nephropathy: A review\u2014How can we optimize the management of Fabry nephropathy?. BMC Nephrol., 15.","DOI":"10.1186\/1471-2369-15-72"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"245","DOI":"10.5935\/0101-2800.20160034","article-title":"Renal involvement in Fabry disease","volume":"38","author":"Abensur","year":"2016","journal-title":"J. Bras. Nefrol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1093\/ndt\/gfy412","article-title":"Renal involvement in Fabry disease","volume":"34","author":"Kantola","year":"2019","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Fall, B., Scott, C.R., Mauer, M., Shankland, S., Pippin, J., Jefferson, J.A., Wallace, E., Warnock, D., and Najafian, B. (2016). Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0168346"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/ndt\/gfp528","article-title":"Scoring system for renal pathology in Fabry disease: Report of the International Study Group of Fabry Nephropathy (ISGFN)","volume":"25","author":"Fogo","year":"2010","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_96","first-page":"49","article-title":"Podocyturia: Why it may have added value in rare diseases","volume":"12","author":"Torra","year":"2018","journal-title":"Clin. Kidney J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5935\/0101-2800.20160008","article-title":"Podocyturia in Fabry disease","volume":"38","author":"Pereira","year":"2016","journal-title":"J. Bras. Nefrol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s40620-016-0271-z","article-title":"Podocyturia is significantly elevated in untreated vs. treated Fabry adult patients","volume":"29","author":"Trimarchi","year":"2016","journal-title":"J. Nephrol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/ndt\/gfx009","article-title":"Parapelvic cysts, a distinguishing feature of renal Fabry disease","volume":"33","author":"Pisani","year":"2018","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ajcp\/8.1.28","article-title":"Peripelvic lymphatic cysts of the kidney: A review of the literature on perinephric cysts","volume":"8","author":"Henthorne","year":"1938","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0022-5347(17)64914-0","article-title":"Peripelvic cysts of the kidney","volume":"87","author":"Jordan","year":"1962","journal-title":"J. Urol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0022-5347(17)42845-X","article-title":"The renal sinus: An imaging review and proposed nomenclature for sinus cysts","volume":"139","author":"Amis","year":"1988","journal-title":"J. Urol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2215\/CJN.02150212","article-title":"Safety and complications of percuta neous kidney biopsies in 715 children and 8573 adults in Norway 1988\u20132010","volume":"7","author":"Vikse","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"611","DOI":"10.23876\/j.krcp.21.056","article-title":"Fabry nephropathy before and after enzyme replacement therapy: Important role of renal biopsy in patients with Fabry disease","volume":"40","author":"Kim","year":"2021","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"298","DOI":"10.25259\/ijn_392_23","article-title":"Zebra Bodies in the Kidney: Is it a Pathognomonic Finding of Fabry Disease?","volume":"35","author":"Patel","year":"2025","journal-title":"Indian J. Nephrol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.xkme.2021.01.006","article-title":"Lupus Nephritis and Hydroxychloroquine-Associated Zebra Bodies: Not Just in Fabry Disease","volume":"3","author":"Manabe","year":"2021","journal-title":"Kidney Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jmsacl.2021.11.004","article-title":"LC-MS lipidomics of renal biopsies for the diagnosis of Fabry disease","volume":"22","author":"Yazd","year":"2021","journal-title":"J. Mass Spectrom. Adv. Clin. Lab"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Rusu, E.E., Zilisteanu, D.S., Ciobotaru, L.M., Gherghiceanu, M., Procop, A., Jurcut, R.O., Dulamea, A.O., and Sorohan, B.M. (2022). The Impact of Kidney Biopsy for Fabry Nephropathy Evaluation on Patients\u2019 Management and Long-Term Outcomes: Experience of a Single Center. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071520"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.ATV.0000209649.60409.38","article-title":"Cardiac and vascular hypertrophy in Fabry disease: Evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition","volume":"26","author":"Barbey","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"508","DOI":"10.23876\/j.krcp.21.235","article-title":"Pathologic findings of Fabry nephropathy: The pivotal role of kidney biopsy","volume":"40","author":"Shin","year":"2021","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/eurheartj\/ehae148","article-title":"Anderson-Fabry disease management: Role of the cardiologist","volume":"45","author":"Pieroni","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: Management and treatment recommendations for adult patients. Fabry disease management recommendations","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"Eur. J. Heart Fail"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Gatterer, C., Beitzke, D., Sunder-Plassmann, G., Friedl, M., Hohensinner, P., Mann, C., Ponleitner, M., Graf, S., and Lenz, M. (2024). NT-proBNP Reflects Left Ventricular Hypertrophy Rather than Left Ventricular Dilatation or Systolic Dysfunction in Patients with Fabry Disease. J. Clin. Med., 13.","DOI":"10.3390\/jcm13195953"},{"key":"ref_115","first-page":"e70008","article-title":"The Utility of High-Sensitivity Troponin to Detect Cardiomyopathy in Patients with Fabry Disease","volume":"66","author":"Wanninayake","year":"2025","journal-title":"JIMD Rep."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Parisi, A., Baldassarre, A., Ferrara, V., Ditaranto, R., Barlocco, F., Lillo, R., Re, F., Marchi, G., Chiti, C., and Di Nicola, F. (2023). Electrocardiogram analysis in Anderson-Fabry disease: A valuable tool for progressive phenotypic expression tracking. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1184361"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Zada, M., Lo, Q., Trivedi, S.J., Harapoz, M., Boyd, A.C., Devine, K., Sadick, N., Tchan, M.C., and Thomas, L. (2022). Electrocardiographic Characteristics and Their Correlation with Echocardiographic Alterations in Fabry Disease. J. Cardiovasc. Dev. Dis., 9.","DOI":"10.3390\/jcdd9010011"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1161\/CIRCULATIONAHA.107.723387","article-title":"Images in cardiovascular medicine. Cryptogenic ventricular arrhythmias and sudden death by Fabry disease: Prominent infiltration of cardiac conduction tissue","volume":"116","author":"Frustaci","year":"2007","journal-title":"Circulation"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/hrt.2010.196162","article-title":"Atrial biopsy evidence of Fabry disease causing lone atrial fibrillation","volume":"96","author":"Chimenti","year":"2010","journal-title":"Heart"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Namdar, M. (2016). Electrocardiographic Changes and Arrhythmia in Fabry Disease. Front. Cardiovasc. Med., 3.","DOI":"10.3389\/fcvm.2016.00007"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s12551-018-0432-5","article-title":"Anderson-Fabry disease in heart failure","volume":"10","author":"Akhtar","year":"2018","journal-title":"Biophys. Rev."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijcard.2021.07.022","article-title":"ECG-based score estimates the probability to detect Fabry Disease cardiac involvement","volume":"339","author":"Figliozzi","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"101439","DOI":"10.1016\/j.cpcardiol.2022.101439","article-title":"Cardiac involvement in Fabry disease and the role of multimodality imaging in diagnosis and disease monitorin","volume":"48","author":"Umer","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","article-title":"Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week","volume":"77","author":"Pieroni","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jcmg.2018.11.039","article-title":"The Role of Cardiac Imaging in the Diagnosis and Management of Anderson-Fabry Disease","volume":"12","author":"Perry","year":"2019","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ehjci\/jeaa101","article-title":"The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage","volume":"22","author":"Augusto","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Averbuch, T., White, J.A., and Fine, N.M. (2023). Anderson-Fabry disease cardiomyopathy: An update on epidemiology, diagnostic approach, management and monitoring strategies. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1152568"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.echo.2021.09.013","article-title":"Burden of Valvular Heart Disease in Patients with Fabry Disease","volume":"35","author":"Yogasundaram","year":"2022","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Cianciulli, T.F., Saccheri, M.C., Llobera, M.N., Balletti, L.R., Beck, M.A., Morita, L.A., and Lax, J.A. (2023). Prevalence of papillary muscle hypertrophy in fabry disease. BMC Cardiovasc. Disord., 23.","DOI":"10.1186\/s12872-023-03463-w"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"131629","DOI":"10.1016\/j.ijcard.2023.131629","article-title":"Diagnostic value of papillary muscle hypertrophy and mitral valve thickness to discriminate cardiac amyloidosis and Fabry disease","volume":"397","author":"Mattig","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1002\/ehf2.14091","article-title":"Heart failure in Fabry disease revisited: Application of current heart failure guidelines and recommendations","volume":"9","author":"Rob","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"ytab124","DOI":"10.1093\/ehjcr\/ytab124","article-title":"Rapidly progressive aortic stenosis treated with transcatheter aortic valve implantation in a patient with Fabry disease: A case report","volume":"5","author":"Saccheri","year":"2021","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.echo.2016.11.014","article-title":"Right Ventricular Hypertrophy, Systolic Function, and Disease Severity in Anderson-Fabry Disease: An Echocardiographic Study","volume":"30","author":"Graziani","year":"2017","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.jcmg.2020.05.011","article-title":"Atrial Dysfunction Assessed by Cardiac Magnetic Resonance as an Early Marker of Fabry Cardiomyopathy","volume":"13","author":"Bernardini","year":"2020","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.ehj.2003.09.017","article-title":"Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium","volume":"24","author":"Moon","year":"2003","journal-title":"Eur. Heart J."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1148\/radiol.2019191385","article-title":"Left Ventricular Hypertrophy and Late Gadolinium Enhancement at Cardiac MRI Are Associated with Adverse Cardiac Events in Fabry Disease","volume":"294","author":"Hanneman","year":"2020","journal-title":"Radiology"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1253\/circj.CJ-15-0054","article-title":"Myocardial T1 mapping","volume":"79","author":"Bulluck","year":"2015","journal-title":"Circ. J."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12968-014-0099-4","article-title":"Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance","volume":"16","author":"Pica","year":"2014","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCIMAGING.112.000070","article-title":"Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping","volume":"6","author":"Sado","year":"2013","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e010171","DOI":"10.1161\/CIRCIMAGING.119.010171","article-title":"Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease","volume":"13","author":"Augusto","year":"2020","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e009052","DOI":"10.1161\/JAHA.118.009052","article-title":"Immune-Mediated Myocarditis in Fabry Disease Cardiomyopathy","volume":"7","author":"Frustaci","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_142","first-page":"1629","article-title":"Correlations Between Cardiac Magnetic Resonance and Myocardial Histologic Findings in Fabry Disease","volume":"16","author":"Ditaranto","year":"2023","journal-title":"J. Am. Coll. Cardiol. Cardiovasc. Imaging"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"i51","DOI":"10.1093\/eurheartjsupp\/suae104","article-title":"Cardiac involvement in Fabry disease: Recent advances, unresolved issues, and unmet needs","volume":"27","author":"Pieroni","year":"2025","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1161\/CIRCULATIONAHA.13.001414","article-title":"Contribution and risks of left ventricular endomyocardial biopsy in patients with cardiomyopathies: A retrospective study over a 28-year period","volume":"128","author":"Chimenti","year":"2013","journal-title":"Circulation"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3988\/jcn.2014.10.2.108","article-title":"Idiopathic small fiber neuropathy: Phenotype, etiologies, and the search for fabry disease","volume":"10","author":"Samuelsson","year":"2014","journal-title":"J. Clin. Neurol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Cort\u00e9s-Saladelafont, E., Fern\u00e1ndez-Mart\u00edn, J., and Ortolano, S. (2023). Fabry Disease and Central Nervous System Involvement: From Big to Small, from Brain to Synapse. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065246"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2169\/internalmedicine.6420-20","article-title":"Characteristics of Neurological Symptoms in Adult Japanese Patients with Fabry Disease","volume":"60","author":"Sawada","year":"2021","journal-title":"Intern. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"fcae095","DOI":"10.1093\/braincomms\/fcae095","article-title":"Small fibre neuropathy in Fabry disease: A human-derived neuronal in vitro disease model and pilot data","volume":"6","author":"Klein","year":"2024","journal-title":"Brain Commun."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/ane.13591","article-title":"Small fiber neuropathy","volume":"145","author":"Finsterer","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"120776","DOI":"10.1016\/j.jns.2023.120776","article-title":"Clinical significance of small nerve fiber involvement in the early diagnosis and treatment of patients with Fabry disease","volume":"453","author":"Kokotis","year":"2023","journal-title":"J. Neurol. Sci."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bj.2021.04.011","article-title":"The correlation of small fiber neuropathy with pain intensity and age in patients with Fabry\u2019s disease: A cross sectional study within a large Taiwanese family","volume":"45","author":"Liao","year":"2022","journal-title":"BioMed J."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/mus.27196","article-title":"Assessment of small fiber neuropathy in patients carrying the non-classical Fabry variant p.D313Y","volume":"63","author":"Muschol","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2326409816661351","DOI":"10.1177\/2326409816661351","article-title":"Small Fiber Neuropathy in Fabry Disease: A Review of Pathophysiology and Treatment","volume":"4","author":"Politei","year":"2016","journal-title":"J. Inborn Errors Metab. Screen."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1212\/WNL.0000000000001450","article-title":"Clinical prodromes of neurodegeneration in Anderson-Fabry disease","volume":"84","author":"Hughes","year":"2015","journal-title":"Neurology"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2326409816661361","DOI":"10.1177\/2326409816661361","article-title":"The central nervous system involvement in Fabry disease: A review","volume":"4","author":"Burlina","year":"2016","journal-title":"J. Inborn Errors Metab. Screen."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3174\/ajnr.A5069","article-title":"Basilar artery changes in Fabry disease","volume":"38","author":"Manara","year":"2017","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Ruiz-Franco, M.L., V\u00e9lez-G\u00f3mez, B., Mart\u00ednez-S\u00e1nchez, P., Gar\u00f3fano-L\u00f3pez, R., G\u00f3mez-Navarro, C., and Arjona-Padillo, A. (2025). Cryptogenic strokes and neurological symptoms of Fabry disease. Front. Neurol., 16.","DOI":"10.3389\/fneur.2025.1529267"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Lelieveld, I.M., B\u00f6ttcher, A., Hennermann, J.B., Beck, M., and Fellgiebel, A. (2015). Eight-year follow-up of neuropsychiatric symptoms and brain structural changes in Fabry disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0137603"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1742-1241.2006.01061.x","article-title":"FOS European investigators. Hyperhidrosis: A new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey","volume":"60","author":"Lidove","year":"2006","journal-title":"Int. J. Clin. Pract."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.anorl.2019.04.014","article-title":"Cochleovestibular manifestations in Fabry disease: Importance of screening and systematic ENT evaluation","volume":"136","author":"Eyermann","year":"2019","journal-title":"Eur. Ann. Otorhinolaryngol. Head Neck Dis."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"10","DOI":"10.20517\/rdodj.2023.46","article-title":"Gastrointestinal involvement in Fabry disease","volume":"3","author":"Politei","year":"2024","journal-title":"Rare Dis. Orphan Drugs J."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Caputo, F., Lungaro, L., Galdi, A., Zoli, E., Giancola, F., Caio, G., De Giorgio, R., and Zoli, G. (2021). Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18063320"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e00633","DOI":"10.14309\/ctg.0000000000000633","article-title":"Gastrointestinal Sensory Neuropathy and Dysmotility in Fabry Disease: Presentations and Effect on Patient\u2019s Quality of Life","volume":"14","author":"Bar","year":"2023","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/1756283X16642936","article-title":"Understanding the gastrointestinal manifestations of Fabry disease: Promoting prompt diagnosis","volume":"9","author":"Karaa","year":"2016","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Gambini, G., Scartozzi, L., Giannuzzi, F., Carl\u00e0, M.M., Boselli, F., Caporossi, T., De Vico, U., Baldascino, A., and Rizzo, S. (2023). Ophthalmic Manifestations in Fabry Disease: Updated Review. J. Pers. Med., 13.","DOI":"10.3390\/jpm13060904"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Giovannetti, F., D\u2019Andrea, M., Bracci, F., Frustaci, A., Chimenti, C., Mangiantini, P., Lambiase, A., and Marenco, M. (2024). Anderson-Fabry Disease: Focus on Ophthalmological Implications. Life, 14.","DOI":"10.3390\/life14121531"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4274\/tjo.galenos.2024.09482","article-title":"Ocular Manifestations of Fabry Disease: Report from a Tertiary Eye Care Center in T\u00fcrkiye","volume":"54","author":"Korkmaz","year":"2024","journal-title":"Turk. J. Ophthalmol."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Pitz, S., Kalkum, G., Arash, L., Karabul, N., Sodi, A., Larroque, S., Beck, M., and Gal, A. (2015). Ocular signs correlate well with disease severity and genotype in Fabry disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120814"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Anker, P., F\u00e9s\u0171s, L., Kiss, N., Lengyel, A., Pinti, \u00c9., Lihacova, I., Lihachev, A., Plorina, E.V., Fekete, G., and Medvecz, M. (2023). A Cross-Sectional Study of the Dermatological Manifestations of Patients with Fabry Disease and the Assessment of Angiokeratomas with Multimodal Imaging. Diagnostics, 13.","DOI":"10.3390\/diagnostics13142368"},{"key":"ref_170","first-page":"81","article-title":"Dermatologic manifestations and neuropathic symptoms in women with Fabry disease","volume":"85","author":"Melpignano","year":"2014","journal-title":"Acta BioMed."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/ijd.14330","article-title":"Angiokeratomas, not everything is Fabry disease","volume":"58","author":"Cuestas","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"San Mill\u00e1n-Tejado, B., Navarro, C., Fern\u00e1ndez-Mart\u00edn, J., Rivera, A., Vi\u00e9itez, I., Teijeira, S., and Ortolano, S. (2023). Morphological Hallmarks of Classical Fabry Disease: An Ultrastructural Study in a Large Spanish Family. J. Clin. Med., 12.","DOI":"10.3390\/jcm12175689"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/1346-8138.17690","article-title":"Cutaneous manifestations of Fabry disease: A systematic review","volume":"52","author":"Folkmann","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_174","first-page":"4","article-title":"A Review of Fabry Disease","volume":"23","author":"Chan","year":"2018","journal-title":"Skin. Ther. Lett."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7655\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:10:46Z","timestamp":1791951046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":174,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["jcm15197655"],"URL":"https:\/\/doi.org\/10.3390\/jcm15197655","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]}}}